Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are effective in improving liver inflammation in patients with MASLD
Rather than diagnosing obesity by BMI alone, it asks whether the excess body fat is actually harming your health
The findings revealed a crucial insight, for some GLP-1 s like Saxenda and Wegovy, the high cost of ongoing use surpasses the cost of RYGB in less than a year and sleeve gastrectomy within nine months
Therefore, the efficacy and specific benefits of GLP-1RAs in HFpEF require further investigation
For each patient, the risk-benefit tradeoff critically depends on a patients clinical characteristics and their preferences and clinicians recommendations, senior study author Rong Xu, PhD, professor and director of the Center for AI in Drug Discovery at Case Western Reserve University, told Healthline